IRadimed CorporationIRMDNASDAQ
LOADING
|||
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q3 2025 | -23.14% |
| Q2 2025 | 40.55% |
| Q1 2025 | 9.52% |
| Q4 2024 | -10.86% |
| Q3 2024 | -20.18% |
| Q2 2024 | -2.42% |
| Q1 2024 | 26.22% |
| Q4 2023 | 43.73% |
| Q3 2023 | -52.95% |
| Q2 2023 | 21.20% |
| Q1 2023 | 31.25% |
| Q4 2022 | 23.00% |
| Q3 2022 | -25.80% |
| Q2 2022 | 27.65% |
| Q1 2022 | 4.90% |
| Q4 2021 | 2.94% |
| Q3 2021 | 5.96% |
| Q2 2021 | -4.65% |
| Q1 2021 | -7.20% |
| Q4 2020 | 7.52% |
| Q3 2020 | -1.20% |
| Q2 2020 | 12.17% |
| Q1 2020 | 13.44% |
| Q4 2019 | 2.65% |
| Q3 2019 | 11.53% |
| Q2 2019 | -6.03% |
| Q1 2019 | -4.12% |
| Q4 2018 | -1.57% |
| Q3 2018 | -5.66% |
| Q2 2018 | 4.26% |
| Q1 2018 | 8.66% |
| Q4 2017 | -8.66% |
| Q3 2017 | -14.77% |
| Q2 2017 | -17.05% |
| Q1 2017 | 48.62% |
| Q4 2016 | -20.33% |
| Q3 2016 | 56.65% |
| Q2 2016 | 24.53% |
| Q1 2016 | -53.13% |
| Q4 2015 | -3.58% |